| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 04/29/2004 | WO2003087367A3 Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
| 04/29/2004 | WO2003086282A3 Nitric oxide donors, compositions and methods of use |
| 04/29/2004 | WO2003082798A8 Natural compounds and derivatives thereof for the prevention and treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications |
| 04/29/2004 | WO2003057134A3 Specific binding agents of human angiopoietin-2 |
| 04/29/2004 | WO2003032913A9 Methods and compositions for targeting proteins across the blood brain barrier |
| 04/29/2004 | WO2003009807A3 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 04/29/2004 | WO2003003972A3 Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof |
| 04/29/2004 | WO2002102787A3 Novel sulfonic acid derivatives |
| 04/29/2004 | WO2002102391A3 Composition comprising nanoparticulate spironolactone |
| 04/29/2004 | WO2002079169A8 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 04/29/2004 | WO2002078626A3 Therapeutic combinations for cardiovascular and inflammatory indications |
| 04/29/2004 | WO2002070669A3 Secreted proteins |
| 04/29/2004 | WO2002064134A8 Use of calcium indomethacin for the treatment of cyclo-oxygenase 2-mediated pathologies |
| 04/29/2004 | WO2002018341A8 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors |
| 04/29/2004 | WO2001082953A8 Methods for treatment of diseases associated with inflammation under non-ischemic conditions |
| 04/29/2004 | US20040082807 Novel salt forms of poorly soluble probucol esters and ethers |
| 04/29/2004 | US20040082798 Novel amino dicarboxylic acid derivatives with pharmaceutical properties |
| 04/29/2004 | US20040082790 Piperidine amides as modulators of chemokine receptor activity |
| 04/29/2004 | US20040082789 Thieno[2,3-c]iosquinolines for use as inhibitors of parp |
| 04/29/2004 | US20040082787 Chemical compounds |
| 04/29/2004 | US20040082781 Bicyclic nitrogenous fused-ring compound |
| 04/29/2004 | US20040082661 Urea derivatives having vanilloid receptor (vr1) antagonist activity |
| 04/29/2004 | US20040082658 Side-chain halogenated amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases |
| 04/29/2004 | US20040082642 Novel estrogen receptor ligands and method III |
| 04/29/2004 | US20040082638 Compounds, compositions and methods |
| 04/29/2004 | US20040082631 Pyrazole compositions useful as inhibitors of ERK |
| 04/29/2004 | US20040082630 1g(a)-Amino-n-hydroxy-acetamide derivatives |
| 04/29/2004 | US20040082623 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists |
| 04/29/2004 | US20040082614 Chlamydia infections; anticholesterol agents; cardiovascular disorders; using mixture containing azithromycin |
| 04/29/2004 | US20040082602 Kinase inhibitor; analgesics; antiarthritic agents; antihistamines; gastrointestinal disorders |
| 04/29/2004 | US20040082600 Bioavailability; oral administering; cardiovascular disorders; sexual disorders |
| 04/29/2004 | US20040082597 Use of CRF antagonists and related compositions |
| 04/29/2004 | US20040082596 Novel carbamate-substituted pyrazolopyridine derivatives |
| 04/29/2004 | US20040082592 Metabotropic glutamate receptor antagonists |
| 04/29/2004 | US20040082589 Quinoline derivatives as nk-3 and nk-2 antagonists |
| 04/29/2004 | US20040082582 Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| 04/29/2004 | US20040082576 Cardiovascular disorders; anticancer agents; antidiabetic agents; dietetics |
| 04/29/2004 | US20040082575 Compounds and methods for modulation of estrogen receptors |
| 04/29/2004 | US20040082569 Novel substituted amides, their preparation and use |
| 04/29/2004 | US20040082567 Antiproliferative agents; anticancer agents; fungicides; antiinflammatory agents |
| 04/29/2004 | US20040082566 Pyrrolidine sulfonamides |
| 04/29/2004 | US20040082564 Methods for treating metabolic diseases using malonyl-coa decarboxylase inhibitors |
| 04/29/2004 | US20040082563 Thrombosis therapy; antitumor agents; anticoagulants; Factor x inhibitors; anticholesterol agents; cardiovascular disorders; antiinflammatory agents |
| 04/29/2004 | US20040082555 Use of gaba, inverse agonists in combination with nicotine receptor partial agonist, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders |
| 04/29/2004 | US20040082551 Novel pyrazoles and their use as p38 kinase inhibitors |
| 04/29/2004 | US20040082548 Cardiovascular disorders; Alzheimer's disease; anticholesterol agents |
| 04/29/2004 | US20040082547 Prevent thrombosis; anticholesterol agents; cardiovascular disorders; anticancer agents |
| 04/29/2004 | US20040082542 Useful as modulators of interaction between receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, beta-amyloid and amphoterin |
| 04/29/2004 | US20040082531 Containing a transcription regulatory sequence derived from Human Cytomegalovirus major immediate early gene that includes exon 1, but not intron A; use of such vectors in vaccine and pharmaceutical compositions and gene therapy |
| 04/29/2004 | US20040082517 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 04/29/2004 | US20040082507 Use of GLP-1 and GLP-2 peptides |
| 04/29/2004 | US20040082504 Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| 04/29/2004 | US20040082499 Perturbed membrane-binding compounds |
| 04/29/2004 | US20040082037 Antiproliferative agents of vascular smooth muscles |
| 04/29/2004 | US20040081972 Detecting antibodies; screening, development therapies for infections, inflammation; polypeptides; monoclonal antibodies |
| 04/29/2004 | US20040081971 Gastrointestinal disorders; cardiovascular disorders; autoimmune diseases; cell proliferation; antiinflammatory agents |
| 04/29/2004 | US20040081715 Cholesterol reducing confectionery comprising a cocoa procyanidin monomer and/or oligomer and a sterol and/or stanol based cholesterol lowering agent |
| 04/29/2004 | US20040081712 Soy protein, phytoestrogens and dietary fibres and compositions |
| 04/29/2004 | US20040081693 Capable of releasing the drug at a constant rate following zero order kinetics for 24 hours or more |
| 04/29/2004 | US20040081645 Glycogen storage disease type II treatment comprising human acid glucosidase, mannitol and sucrose in aqueous solution |
| 04/29/2004 | US20040081624 Mixture containing high volatility carrier; vaporization; mixing with air |
| 04/29/2004 | DE10294485T5 Mit Mnk-Kinase homologe Proteine, die in die Regulation der Energiehomöostase und den Organellenmetabolismus involviert sind Mnk homologous proteins with kinase, that are involved in the regulation of energy homeostasis and the metabolism organelle |
| 04/29/2004 | CA2503075A1 Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
| 04/29/2004 | CA2502505A1 Alpha-phenyl acetanilide derivatives and their human therapeutic application |
| 04/29/2004 | CA2502284A1 Bisphosphonates for the treatment of antheroscleorosis and devices comprising them |
| 04/29/2004 | CA2502211A1 Azo compounds for type i phototherapy |
| 04/29/2004 | CA2502032A1 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 04/29/2004 | CA2502021A1 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 04/29/2004 | CA2500417A1 Neurotrophic factor production promoter |
| 04/28/2004 | EP1413587A2 Modified complement system regulator |
| 04/28/2004 | EP1413580A1 Furanone derivatives as inhibitors of Cathepsin S |
| 04/28/2004 | EP1413579A1 Imidazoline derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| 04/28/2004 | EP1413578A1 Novel crystal of arylethenesulfonamide derivative and process for producing the same |
| 04/28/2004 | EP1413576A2 Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors |
| 04/28/2004 | EP1413331A2 Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) for vascular indications |
| 04/28/2004 | EP1413315A1 Sustained-release medicines |
| 04/28/2004 | EP1413314A1 Medicinal compositions |
| 04/28/2004 | EP1413299A2 Use of deprenyl analogues to maintain, prevent loss, or recover nerve cell function |
| 04/28/2004 | EP1413297A1 Cyclosporin-containing soft capsule preparations |
| 04/28/2004 | EP1413295A1 Sustained release composition for oral administration of drugs |
| 04/28/2004 | EP1412492A2 Regulator of calcineurin |
| 04/28/2004 | EP1412479A2 Cells of the cardiomyocyte lineage produced from human pluripotent stem cells |
| 04/28/2004 | EP1412388A1 Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin |
| 04/28/2004 | EP1412386A2 USE OF PEPTIDE FRAGMENTS OF THE CALCIUM CHANNEL $g(A)-1 SUBUNIT, OPTIONALLY COMPRISING MUTATIONS, FOR SCREENING MOLECULES OF THERAPEUTIC INTEREST |
| 04/28/2004 | EP1412379A2 Antigenic polypeptides |
| 04/28/2004 | EP1412374A2 Novel pgc-1 isoforms and uses therefor |
| 04/28/2004 | EP1412371A1 IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| 04/28/2004 | EP1412364A1 Platelet adp receptor inhibitors |
| 04/28/2004 | EP1412361A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists |
| 04/28/2004 | EP1412357A1 Beta-amino tetrahydroimidazo(1,2-a)pyrazines and tetrahydrotriazolo(4,3-a)pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 04/28/2004 | EP1412354A1 DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF THE TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A 2a? RECEPTOR AND THEIR USE AS MEDICAMENTS |
| 04/28/2004 | EP1412352A1 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands |
| 04/28/2004 | EP1412343A1 New compounds, which are potent inhibitors of na+/ca2+ exchange mechanism and are useful in the treatment of arrhythmias |
| 04/28/2004 | EP1412340A2 Process for the preparation of citalopram hydrobromide |
| 04/28/2004 | EP1412338A1 1,3,5-triazine-2,4,6-triones, preparation and use as gonadotropin-releasing hormone receptor antagonists |
| 04/28/2004 | EP1412330A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 04/28/2004 | EP1412327A2 Inhibitors of protein kinase for the treatment of disease |
| 04/28/2004 | EP1412326A1 Butyric acid derivatives |
| 04/28/2004 | EP1412320A1 Linked cyclitols and their polysulfated derivatives |
| 04/28/2004 | EP1412317A1 Retinoid derivatives with antiangiogenic, antitumor and proapoptotic activities |